Key points from article :
ADx NeuroSciences and Alamar Biosciences have formed a strategic partnership to enhance biomarker assay development, particularly benefiting neurodegenerative disease research. By integrating ADx’s experience in neurodegenerative biomarker creation with Alamar’s advanced NULISA™ (Nucleic Acid Linked Immuno-Sandwich Assay) platform and ARGO™ HT System, this collaboration aims to expedite biomarker analysis for therapies targeting conditions like Alzheimer’s, Parkinson’s, and ALS. The high sensitivity of the NULISA platform allows for ultra-precise biomarker detection, potentially supporting earlier diagnosis and therapeutic monitoring.
This partnership will deliver customized assay solutions tailored to meet specific pharmaceutical needs, enabling companies to advance neurodegenerative therapeutics more effectively. By leveraging cutting-edge technology and expertise, ADx and Alamar offer pharmaceutical firms advanced tools for quantifying critical biomarkers across various stages of drug development—from early preclinical research through to final stages.
The addition of the NULISA platform strengthens ADx’s capability to provide comprehensive biomarker assay options. Offering such a high level of sensitivity aligns with ADx’s goal to support pharmaceutical partners in identifying relevant biomarkers at critical phases of drug discovery and testing. The collaboration underscores a shared commitment to innovation in biomarker detection, expanding the possibilities for early diagnosis and treatment of neurodegenerative diseases.
Alamar Biosciences focuses on precision proteomics, with its NULISA Platform designed for single-digit attomolar sensitivity, a level that surpasses most existing detection technologies. ADx, meanwhile, has a track record of developing biomarker tools for Alzheimer’s and Parkinson’s, supporting drug efficacy assessments and patient selection. Together, these advancements may improve outcomes in clinical research, offering the scientific community enhanced resources for exploring novel therapeutics targeting debilitating neurodegenerative conditions.
